TLR8 (human, Q9NR97) — curation notes

Batch 1 of the INNATE_IMMUNITY project (Toll/TLR axis). Reviewed immediately after
TLR7 (Q9NYK1), with which TLR8 shares its PAINT node, most of its electronic
annotations, and several references.

Deep research: TLR8-deep-research-falcon.md (Edison/Falcon) was produced and
read. Its citation keys are internal document handles rather than PMIDs, so it is
used here only for orientation; every claim below is anchored to a cached
publication in publications/.

What TLR8 is

Endosomal single-pass type I membrane pattern-recognition receptor of the same
subfamily as TLR7 and TLR9: LRR ectodomain, one transmembrane helix, cytoplasmic
TIR domain. It is the most highly expressed nucleic-acid-sensing TLR in the human
myeloid compartment.

Ligands: uridine plus a short oligonucleotide, at two sites.
- PMID:25599397
- PMID:25599397
- PMID:25599397

Both ligands are generated in situ by RNase T2:
- PMID:31778653
- PMID:31778653

Note the contrast with TLR7, which matters for the ligand-specific pathway terms:
TLR7's site 1 takes guanosine, TLR8's takes uridine, and TLR7 has a second
site absent from TLR8 PMID:27742543. The two receptors nonetheless share
synthetic agonists (R-848) PMID:12032557.

Viral ssRNA.
- PMID:14976262
- PMID:33718825

Activation mechanism: Z-loop cleavage then ligand-induced dimer reorganisation.
- PMID:26929371
- PMID:23520111
- PMID:25297876

Localisation: early endosome and ER — explicitly not late endosome, lysosome or
Golgi.
This is the sharpest difference from TLR7/TLR9 and the main reason several
location rows were demoted.
- PMID:22164301
- PMID:22164301
- PMID:22164301
- PMID:22164301

Disease. X-linked gain-of-function variants cause IMD98 (neutropenia,
lymphoproliferation, autoinflammation, bone-marrow failure), mostly as somatic
mosaicism.
- PMID:33512449

Annotation-level findings

  1. Localisation rows contradicted by PMID:22164301. The two GO:0000139 Golgi membrane Reactome TAS rows and the two GO:0036020 endolysosome membrane rows
    (ARBA IEA + Reactome TAS) assert compartments in which endogenous TLR8 was
    explicitly not found in human monocytes. They are marked
    MARK_AS_OVER_ANNOTATED, with GO:0031901 early endosome membrane proposed for
    the endolysosome rows. GO:0010008 endosome membrane (EXP, IEA, two Reactome
    rows) and the ER membrane Reactome rows are accepted.

  2. GO:0009897 external side of plasma membrane (IDA, PMID:24942581) is
    contradicted by the paper it cites.
    The cached record is abstract-only, so I
    retrieved the open PMC full text (PMC4136363). TLR8 is assayed there — 26
    mentions — which is exactly why the row cannot be dismissed as a wrong
    identifier. But the measurement is explicitly intracellular: "Intracellular TLR8
    staining was performed using the Cytofix/Cytoperm Fixation/Permeabilization
    Solution Kit", and the discussion speaks of "the increase in expression of
    pattern recognition receptors such as intracellular TLR8". The same paper's two
    other TLR8 rows (GO:0034158, GO:0003727) are supported by its ssRNA40
    stimulation experiments and are accepted; the surface-location row is REMOVEd.

  3. GO:0003725 double-stranded RNA binding, two IDA rows. PMID:33718825 used
    GU-rich single-stranded RNA throughout (its abstract says so), and PMID:16111635
    is the nucleoside-modification study of RNA sensing. TLR8's structurally defined
    sites bind uridine and a short oligonucleotide PMID:25599397. Both rows MODIFY
    to GO:0003727 single-stranded RNA binding, which TLR8 already carries.

  4. GO:0003677 DNA binding (IDA, PMID:16123302). The Treg-reversal paper used
    "synthetic and natural ligands for human TLR8"; DNA sensing is TLR9's function,
    and the TLR8 ligand-binding sites are defined for uridine and short RNA
    oligonucleotides. Cached record is abstract-only, so the row is not removed on
    an unverifiable mis-attribution claim; it is marked MARK_AS_OVER_ANNOTATED.
    GO:0003723 RNA binding (TAS, same paper) MODIFYs to the informative
    GO:0003727.

  5. GO:0016064 immunoglobulin mediated immune response (TAS, PMID:16123302).
    The cited paper concerns reversal of CD4+ regulatory T cell suppression; nothing
    in it bears on immunoglobulin-mediated immunity, and TAS is not experimental
    evidence to defer to. REMOVE.

  6. Type II interferon. As for TLR7, the IDA PMID:16286015 row rests on a paper
    measuring IFN-alpha/beta and IFN-lambda only, so it MODIFYs to GO:0034346 positive regulation of type III interferon production (the decision already
    taken in the TLR9 review). Unlike TLR7 — where PMID:32706371 shows IFN-gamma
    loss in TLR7-deficient patients — there is no TLR8-specific IFN-gamma evidence
    in the reviewed literature, so the ARBA IEA row is MARK_AS_OVER_ANNOTATED,
    matching TLR9.

  7. GO:0071260 cellular response to mechanical stimulus (IEP, PMID:19593445).
    Same wrong-reference problem as TLR7 and TLR3: the identifier resolves to
    "Expression of the Bcl-2 protein BAD promotes prostate cancer growth", whose
    cached full text has no occurrence of "TLR" or "toll". UNDECIDED, with
    reference_review.correctness: WRONG_IDENTIFIER.

  8. GO:0005515 protein binding, two IPI rows (UNC93B1). Uninformative. TLR8 is
    the client of UNC93B1 and the biology is trafficking; the BioPlex row
    (PMID:33961781) is a proteome-scale interactome screen with no functional
    assignment. REMOVE both, mirroring the TLR3/TLR7 handling. Removal does not
    dispute either interaction — PMID:22164301 establishes the UNC93B1 association
    directly.

  9. Plasma membrane IBA. The is_active_in GO:0005886 row sits at the TLR7/8/9
    node. For TLR8 the endosomal restriction is not merely where it signals but a
    prerequisite: the Z-loop must be cleaved by endosomal proteases before the
    receptor can dimerise at all [PMID:26929371, PMID:25297876]. KEEP_AS_NON_CORE,
    with the node-level question raised.

  10. GO:0038023 signaling receptor activity and GO:0045087 (NAS,
    PMID:12032557).
    Author-statement rows from the R-848 correspondence. Both are
    true but generic; the receptor-activity row MODIFYs to GO:0038187 pattern recognition receptor activity, which TLR8 already carries by IBA and which is
    what the structures establish.

Deep-research cross-check (2026-09-30)

The Falcon report had already been read for orientation when the review was
written; this pass re-compared it against each decision.